Dr. A. Ari Hakimi

Dr. A. Ari Hakimi, MD, is a urologic surgeon specializing in the care of patients with urologic malignancies, with a particular focus on kidney tumors. He practices at Memorial Sloan Kettering Cancer Center, where he works closely with colleagues in medical oncology, radiology, and pathology to deliver comprehensive, multidisciplinary care. Recognizing that the treatment of kidney cancer is complex and continues to evolve, Dr. Hakimi ensures that patients have a thorough understanding of all available options. His surgical practice encompasses open, endoscopic, and minimally invasive robotic techniques, with the approach tailored to each patient's unique circumstances.

Dr. Hakimi is deeply committed to advancing the understanding of kidney cancer through genomic research. His laboratory work focuses on uncovering the mechanisms of kidney cancer initiation and progression, utilizing genomic sequencing approaches in close collaboration with computational and molecular biologists. He has lectured and published extensively on the genomic underpinnings of kidney cancer and has identified several mutations that predict more aggressive disease. His contributions to the field have been recognized with awards from the American Society of Clinical Oncology, the Society of Urologic Oncology, and the Kidney Cancer Association. A central goal of his research is to translate laboratory discoveries into clinically meaningful improvements for his patients.

At the core of both his clinical and research work is a commitment to individualizing patient care. Dr. Hakimi and his team prioritize open communication, guiding patients through every step of the surgical process from initial consultation through recovery. By integrating cutting-edge genomic insights with a patient-centered approach to surgery, he works to ensure that each patient receives care that is as precise and personalized as possible. His efforts continue to shape the evolving landscape of kidney cancer treatment.